Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study

医学 内科学 肿瘤科 转移性乳腺癌 队列 乳腺癌 生殖系 临床终点 危险系数 实体瘤疗效评价标准 临床试验 癌症 置信区间 临床研究阶段 生物 基因 生物化学
作者
Gordan Srkalović,Michael Rothe,Pam K. Mangat,Elizabeth Garrett‐Mayer,Eugene R. Ahn,Gregory Brouse,John K. Chan,Inderjit Mehmi,Maya Khalil,Herbert L. Duvivier,Anu Gaba,Harshraj Leuva,Ramya Thota,K. Yost,Gina N. Grantham,Abigail Gregory,Dominique C. Hinshaw,Susan Halabi,Richard L. Schilsky
出处
期刊:JCO precision oncology [Lippincott Williams & Wilkins]
卷期号: (8)
标识
DOI:10.1200/po.24.00026
摘要

PURPOSE The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with various solid tumors with germline or somatic BRCA1/2 mutations treated with talazoparib are reported. METHODS Eligible patients had advanced solid tumors, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. Patients with germline BRCA-mutated human epidermal growth factor receptor 2–negative locally advanced or metastatic breast cancer were not eligible for this study. Primary end point was disease control (DC) determined by investigator assessment of objective response (OR) or stable disease (SD) of at least 16 weeks duration (SD16+). The results were evaluated on the basis of a one-sided exact binomial test with a null DC rate of 15% versus 35% (power = 0.82; α = .10). Secondary end points were OR, progression-free survival, overall survival, duration of response, duration of SD, and safety. RESULTS Twenty-eight patients (20 cancer types) with BRCA1/2 mutations were enrolled from December 2019 to September 2021 and collapsed into a single histology pooled cohort for analysis. All patients were evaluable for efficacy. One complete response, nine partial response, and six SD16+ were observed for DC and OR rates of 57% (one-sided 90% CI, 43 to 100) and 36% (95% CI, 19 to 56), respectively. The null hypothesis of a 15% DC rate was rejected ( P < .001). Patients with OR had the following tumor types: breast (2), nonmelanoma skin, mesothelioma, stomach, uterus, non–small cell lung cancer, ovary, hepatocellular carcinoma, and pancreas. Thirteen patients had at least one grade 3-5 adverse event (AE) or serious AE at least possibly related to talazoparib. All were consistent with the drug label except bilirubin increase and hyponatremia (both grade 3 AEs). CONCLUSION Talazoparib demonstrated antitumor activity in patients with advanced solid tumors and BRCA1/2 mutations, including cancer types for which poly ADP-ribose polymerase inhibitors are not yet US Food and Drug Administration–approved.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
tao发布了新的文献求助10
刚刚
大鹅完成签到,获得积分10
刚刚
1秒前
wwwy007完成签到,获得积分10
1秒前
千千完成签到,获得积分10
1秒前
白云黑土的应助被tt采纳,获得10
1秒前
刘承昭发布了新的文献求助10
1秒前
lx完成签到 ,获得积分10
2秒前
Lucas的应助被曹牛牛采纳,获得10
2秒前
fortuna发布了新的文献求助10
2秒前
二指弹完成签到 ,获得积分10
2秒前
2秒前
3秒前
长阶词完成签到,获得积分10
3秒前
我是老大的应助被duduqiang采纳,获得10
3秒前
李嘉怡完成签到,获得积分20
3秒前
自由逐风的小驴子完成签到,获得积分10
3秒前
3秒前
3秒前
ZHI完成签到,获得积分10
3秒前
bkagyin的应助被zhu采纳,获得10
4秒前
小肖没烦恼完成签到,获得积分10
4秒前
顾矜的应助被刘承昭采纳,获得10
5秒前
英吉利25发布了新的文献求助50
5秒前
5秒前
贺鹏霖完成签到,获得积分10
5秒前
5秒前
quester完成签到,获得积分10
5秒前
6秒前
Ni1101发布了新的文献求助10
6秒前
6秒前
lucy完成签到,获得积分10
7秒前
谦让疾发布了新的文献求助30
7秒前
cc完成签到,获得积分10
8秒前
汉堡包的应助被犹豫的牛排采纳,获得30
9秒前
mw完成签到,获得积分20
9秒前
过时的疾发布了新的文献求助10
10秒前
10秒前
10秒前
852的应助被黑猫黑猫采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160467
求助须知:如何正确求助?哪些是违规求助? 9555463
关于积分的说明 21728123
捐赠科研通 7750270
什么是DOI,文献DOI怎么找? 3427393
关于科研通互助平台的介绍 2552425
邀请新用户注册赠送积分活动 2471741